Before revision: This is especially true in combination with aromatic L-amino acid decarboxylase inhibitors (AAAD inhibitors; also known as DOPA decarboxylase (DDC) inhibitors) such as carbidopa and benserazide.
After revision: This is especially true in the case of the brain in combination with peripherally selective aromatic L-amino acid decarboxylase inhibitors (AAAD inhibitors; also known as DOPA decarboxylase (DDC) inhibitors) such as carbidopa and benserazide.